Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06790121
PHASE2

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

Sponsor: Sanofi

View on ClinicalTrials.gov

Summary

This is a parallel, Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of lunsekimig monotherapy in adult participants (aged 18 to 80 years, inclusive) with moderate-to-severe atopic dermatitis (AD). This study explores the efficacy and safety of 3 subcutaneous (SC) dose regimens of lunsekimig in adult participants with moderate-to-severe AD who have a documented history, within 6 months prior to baseline, of an inadequate response to topical treatments or for whom topical therapies are not advised. The study consists of 6 arms: 3 parallel dosing regimens and matching placebo arms. Additionally, participants have the option of engaging in a dense pharmacokinetic/pharmodynamic (PK/PD) sampling subgroup. The study duration will be up to approximately 36 weeks, including up to 4 weeks of screening, 24 weeks of treatment period and an 8-week safety follow-up period.

Official title: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of 3 Subcutaneous Dose Regimens of Lunsekimig (SAR443765) in Adult Participants With Moderate-to-severe Atopic Dermatitis

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2025-01-30

Completion Date

2026-04-13

Last Updated

2026-02-24

Healthy Volunteers

No

Interventions

DRUG

Lunsekimig

Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

DRUG

Placebo

Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

Locations (52)

T. Joseph Raoof MD Inc-Site Number: 8400004

Encino, California, United States

Integrative Skin Science and Research-Site Number: 8400002

Sacramento, California, United States

Clinical Trials Research Institute-Site Number: 8400003

Thousand Oaks, California, United States

Skin Care Research-Site Number: 8400013

Boca Raton, Florida, United States

Driven Research LLC-Site Number: 8400020

Coral Gables, Florida, United States

Revival Research Institute, LLC-Site Number: 8400021

Evans, Georgia, United States

Treasure Valley Medical Research-Site Number: 8400026

Boise, Idaho, United States

Southern Indiana Clinical Trials-Site Number: 8400024

New Albany, Indiana, United States

Indiana Clinical Trials Center, P.C.-Site Number: 8400018

Plainfield, Indiana, United States

Optima Research-Site Number: 8400019

Plainfield, Indiana, United States

Options Research Group-Site Number: 8400012

West Lafayette, Indiana, United States

DS Research - Kentucky-Site Number: 8400005

Louisville, Kentucky, United States

Clinical Trials Management LLC-Site Number: 8400010

Covington, Louisiana, United States

Beacon Clinical Research-Site Number: 8400006

Quincy, Massachusetts, United States

Somerset Skin Centre-Site Number: 8400009

Troy, Michigan, United States

Medisearch LLC-Site Number: 8400017

Saint Joseph, Missouri, United States

Skin Cancer and Dermatology Institute-Site Number: 8400011

Reno, Nevada, United States

Icahn School of Medicine at Mount Sinai-Site Number: 8400023

New York, New York, United States

Red River Research Partners-Site Number: 8400008

Fargo, North Dakota, United States

Health Concepts-Site Number: 8400025

Rapid City, South Dakota, United States

DermResearch-Site Number: 8400014

Austin, Texas, United States

Progressive Clinical Research-Site Number: 8400001

San Antonio, Texas, United States

Burien US-WA 98168 Dermatology of Seattle and Bellevue-Site Number: 8400015

Burien, Washington, United States

Investigational Site Number: 0203003

Prague, Czechia

Investigational Site Number: 0203001

Prague, Czechia

Investigational Site Number: 0203004

Prague, Czechia

Investigational Site Number: 0203002

Prague, Czechia

Investigational Site Number: 3920005

Asahikawa-shi, Japan

Investigational Site Number: 3920003

Fukuoka, Japan

Investigational Site Number: 3920004

Kofu, Japan

Investigational Site Number: 3920002

Mibu, Japan

Investigational Site Number: 3920006

Nerima-ku, Japan

Investigational Site Number: 3920001

Ōta-ku, Japan

Investigational Site Number: 3920008

Tachikawa-shi, Japan

Investigational Site Number: 3920007

Yokohama, Japan

Investigational Site Number: 6160014

Bochnia, Poland

Investigational Site Number: 6160006

Bydgoszcz, Poland

Investigational Site Number: 6160010

Jelenia Góra, Poland

Investigational Site Number: 6160007

Katowice, Poland

Investigational Site Number: 6160003

Katowice, Poland

Investigational Site Number: 6160013

Lublin, Poland

Investigational Site Number: 6160001

Mikołów, Poland

Investigational Site Number: 6160011

Nowa Sól, Poland

Investigational Site Number: 6160015

Ostrowiec Swietokrzyskie, Poland

Investigational Site Number: 6160009

Poznan, Poland

Investigational Site Number: 6160012

Sosnowiec, Poland

Investigational Site Number: 6160004

Szczecin, Poland

Investigational Site Number: 6160017

Warsaw, Poland

Investigational Site Number: 6160018

Warsaw, Poland

Investigational Site Number: 6160002

Warsaw, Poland

Investigational Site Number: 6160005

Wroclaw, Poland

Investigational Site Number: 6160016

Łodź, Poland